Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab for Prurigo Nodularis – Randomized Double-Blind Placebo-Controlled Phase 3 Trial
2019-004789-17Phase 3Completed
- Sponsor
- Galderma
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prurigo nodularis (PN) comparing Nemolizumab with Placebo (2 arms). Primary endpoint: Investigator Global Assessment (IGA) response. Started Apr 2020; status: completed.
02
Drugs
nemolizumab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on 2019-004789-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004789-17.